Petros Pharmaceuticals, Inc.(PTPI)Earnings, Financials & Key Ratios
PTPI•NASDAQ
$0.01
$50564 mkt cap·Price updated May 7, 2026
AboutPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.Show more
- Revenue$5M-12.2%
- EBITDA-$15M-44.4%
- Net Income-$14M-75.4%
- EPS (Diluted)-3.34+47.4%
- Gross Margin76.28%+6.0%
- EBITDA Margin-288.26%-64.5%
- Operating Margin-345.84%-47.9%
- Net Margin-280.1%-99.8%
- ROE-571.33%-921.2%
- ROIC-730.89%-779.5%
- Interest Coverage-31.52-24.1%
PTPI Key Insights
Petros Pharmaceuticals, Inc. (PTPI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 20.0% over 5 years
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PTPI Price & Volume
Petros Pharmaceuticals, Inc. (PTPI) stock price & volume — 10-year historical chart
Loading chart...
PTPI Growth Metrics
Petros Pharmaceuticals, Inc. (PTPI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-19.98%
3 Years-13.18%
TTM-81.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-48.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-130.53%
Return on Capital
10 Years-84.45%
5 Years-95.9%
3 Years-115.66%
Last Year-226.19%
PTPI Peer Comparison
Petros Pharmaceuticals, Inc. (PTPI) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 HIMS | 6.63B | 25.67 | 50.32 | 59% | 5.47% | 23.73% | 2.07 | |
 MNKD | 1.1B | 3.55 | 177.50 | 22.23% | -6.63% | |||
 LLY | 921.16B | 974.96 | 42.48 | 44.7% | 34.98% | 101.17% | 1.60 | |
 PFE | 150.63B | 26.48 | 19.47 | -1.65% | 11.83% | 8.34% | 0.78 | |
 JAZZ | 14.24B | 226.96 | -38.86 | 4.88% | 0.66% | 0.71% | 1.26 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SUPN | 3.01B | 52.28 | -76.88 | 8.63% | -3.74% | -2.73% | 0.04 |
Compare PTPI vs Peers
Petros Pharmaceuticals, Inc. (PTPI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTPI Income Statement
Petros Pharmaceuticals, Inc. (PTPI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 14.05M | 15.58M | 9.56M | 7.81M | 5.99M | 5.82M | 5.11M | 725.4K |
| Revenue Growth % | - | 10.86% | -38.63% | -18.29% | -23.29% | -2.83% | -12.2% | -81.97% |
| Cost of Goods Sold | 10.48M | 12.72M | 4.05M | 1.6M | 2.29M | 1.63M | 1.21M | 264.75K |
| COGS % of Revenue | 74.59% | 81.65% | 42.33% | 20.48% | 38.21% | 28.02% | 23.72% | - |
| Gross Profit | 3.57M▲ 0% | 2.86M▼ 19.9% | 5.51M▲ 92.8% | 6.21M▲ 12.7% | 3.7M▼ 40.4% | 4.19M▲ 13.2% | 3.9M▼ 7.0% | 460.65K▲ 0% |
| Gross Margin % | 25.41% | 18.35% | 57.67% | 79.52% | 61.79% | 71.98% | 76.28% | 63.5% |
| Gross Profit Growth % | - | -19.93% | 92.83% | 12.67% | -40.39% | 13.19% | -6.96% | - |
| Operating Expenses | 11.22M | 25.02M | 22.8M | 24.26M | 23.62M | 17.81M | 21.58M | 13.84M |
| OpEx % of Revenue | 79.86% | 160.61% | 238.46% | 310.57% | 394.16% | 305.86% | 422.12% | - |
| Selling, General & Admin | 11.22M | 19.73M | 15.67M | 15.59M | 12.21M | 9.26M | 8.75M | 4.71M |
| SG&A % of Revenue | 79.86% | 126.64% | 163.97% | 199.63% | 203.76% | 159.07% | 171.15% | - |
| Research & Development | 0 | 0 | 459.64K | 1.79M | 1.74M | 2.41M | 2.62M | 101.94K |
| R&D % of Revenue | - | - | 4.81% | 22.9% | 29.04% | 41.38% | 51.15% | - |
| Other Operating Expenses | 0 | 5.29M | 6.66M | 6.88M | 9.67M | 6.14M | 10.21M | 1.99M |
| Operating Income | -7.65M▲ 0% | -19.31M▼ 152.4% | -17.28M▲ 10.5% | -18.05M▼ 4.4% | -19.92M▼ 10.3% | -13.62M▲ 31.6% | -17.68M▼ 29.8% | -13.38M▲ 0% |
| Operating Margin % | -54.45% | -123.98% | -180.78% | -231.05% | -332.37% | -233.88% | -345.84% | -1844.61% |
| Operating Income Growth % | - | -152.44% | 10.51% | -4.43% | -10.35% | 31.63% | -29.83% | - |
| EBITDA | 414.72K | -14.02M | -10.53M | -11.17M | -14.2M | -10.2M | -14.74M | -12.01M |
| EBITDA Margin % | 2.95% | -90.01% | -110.14% | -143% | -236.98% | -175.22% | -288.26% | -1655.05% |
| EBITDA Growth % | - | -3480.83% | 24.91% | -6.09% | -27.12% | 28.15% | -44.44% | -15.29% |
| D&A (Non-Cash Add-back) | 8.06M | 5.29M | 6.75M | 6.88M | 5.72M | 3.42M | 2.94M | 1.38M |
| EBIT | -20.63M | -19.31M | -18.96M | -8.62M | -19.44M | -7.63M | -13.76M | -13.29M |
| Net Interest Income | 0 | -13.84M | -3.05M | -368.66K | -581.82K | -20.83K | -189.14K | 60.94K |
| Interest Income | 11.86M | 0 | 0 | 0 | 14.19K | 515.31K | 371.77K | 228.39K |
| Interest Expense | 0 | 13.84M | 3.05M | 368.66K | 596.02K | 536.14K | 560.91K | 167.46K |
| Other Income/Expense | -24.84M | -13.84M | -4.73M | 9.06M | -121.82K | 5.45M | 3.36M | -56.67K |
| Pretax Income | -32.49M▲ 0% | -33.16M▼ 2.1% | -22.01M▲ 33.6% | -8.99M▲ 59.2% | -20.04M▼ 123.0% | -8.16M▲ 59.3% | -14.32M▼ 75.4% | -13.44M▲ 0% |
| Pretax Margin % | -231.2% | -212.86% | -230.27% | -115.05% | -334.4% | -140.2% | -280.1% | -1852.35% |
| Income Tax | -13.37K | -645.87K | -1.43M | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.04% | 1.95% | 6.48% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -32.47M▲ 0% | -32.51M▼ 0.1% | -20.59M▲ 36.7% | -8.99M▲ 56.3% | -20.04M▼ 123.0% | -8.16M▲ 59.3% | -14.32M▼ 75.4% | -7.02M▲ 0% |
| Net Margin % | -231.1% | -208.71% | -215.35% | -115.05% | -334.4% | -140.2% | -280.1% | -968.2% |
| Net Income Growth % | - | -0.12% | 36.68% | 56.35% | -122.97% | 59.26% | -75.41% | -48.57% |
| Net Income (Continuing) | -32.47M | -32.51M | -20.59M | -8.99M | -20.04M | -8.16M | -14.32M | -13.44M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -499.18K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -324.73▲ 0% | -132.16▲ 59.3% | -38.55▲ 70.8% | -8.25▲ 78.6% | -9.68▼ 17.3% | -6.35▲ 34.4% | -3.34▲ 47.4% | -0.17▲ 0% |
| EPS Growth % | - | 59.3% | 70.83% | 78.6% | -17.33% | 34.4% | 47.4% | -130.53% |
| EPS (Basic) | -324.73 | -132.16 | -38.55 | -8.25 | -9.68 | -6.35 | -3.34 | - |
| Diluted Shares Outstanding | 100K | 246K | 534.07K | 1.09M | 2.07M | 2.18M | 8.03M | 42.28M |
| Basic Shares Outstanding | 100K | 246K | 534.07K | 1.09M | 2.07M | 1.29M | 8.03M | 42.28M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PTPI Balance Sheet
Petros Pharmaceuticals, Inc. (PTPI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.81M | 12.09M | 25.91M | 30.54M | 14.67M | 20.39M | 7.29M | 6.13M |
| Cash & Short-Term Investments | 2.79M | 2.15M | 17.14M | 23.85M | 9.43M | 13.34M | 3.71M | 6.07M |
| Cash Only | 2.79M | 2.15M | 17.14M | 23.85M | 9.43M | 13.34M | 3.71M | 6.07M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.51M | 3.85M | 5.15M | 3.06M | 2.11M | 2.23M | 416.08K | 0 |
| Days Sales Outstanding | 91.23 | 90.17 | 196.75 | 143.19 | 128.54 | 139.56 | 29.71 | 52.34 |
| Inventory | 6.49M | 2.2M | 760.53K | 519.65K | 1.82M | 1.61M | 3M | 0 |
| Days Inventory Outstanding | 226.03 | 63.26 | 68.6 | 118.58 | 289.38 | 360.34 | 902.65 | 1.03K |
| Other Current Assets | 1.64M | 1.94M | 1.48M | 1.53M | 802.21K | 816.21K | 6.53K | 63.2K |
| Total Non-Current Assets | 51.08M | 46.28M | 43.95M | 36.85M | 17.75M | 13.41M | 3.34M | 0 |
| Property, Plant & Equipment | 0 | 69.84K | 643.78K | 524.95K | 397.65K | 255.22K | 136.68K | 0 |
| Fixed Asset Turnover | - | 223.05x | 14.85x | 14.88x | 15.07x | 22.81x | 37.40x | 21.23x |
| Goodwill | 2.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 44.1M | 38.81M | 32.16M | 25.29M | 12.24M | 8.97M | 3.2M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 4.53M | 7.4M | 11.14M | 11.03M | 5.11M | 4.18M | 0 | 3.14M |
| Total Assets | 66.89M▲ 0% | 58.37M▼ 12.7% | 69.85M▲ 19.7% | 67.39M▼ 3.5% | 32.42M▼ 51.9% | 33.8M▲ 4.2% | 10.64M▼ 68.5% | 6.13M▲ 0% |
| Asset Turnover | 0.21x | 0.27x | 0.14x | 0.12x | 0.18x | 0.17x | 0.48x | 0.07x |
| Asset Growth % | - | -12.74% | 19.68% | -3.53% | -51.89% | 4.24% | -68.53% | -251.42% |
| Total Current Liabilities | 38.54M | 41.1M | 41.89M | 30.98M | 7.07M | 10.77M | 18.03M | 2.77M |
| Accounts Payable | 1.75M | 3.78M | 5.61M | 4.56M | 1.81M | 1.71M | 2.33M | 421.14K |
| Days Payables Outstanding | 61.02 | 108.38 | 505.99 | 1.04K | 287.99 | 383.36 | 700.97 | 1.54K |
| Short-Term Debt | 19.3M | 6.68M | 7.18M | 0 | 1.09M | 1.16M | 7.25M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | -125.58K | 0 | 2.05M | 0 | 1.72M |
| Other Current Liabilities | 12.57M | 453.09K | 26.04M | 22.93M | 822.39K | 1.11M | 7.1M | 2.34M |
| Current Ratio | 0.41x | 0.29x | 0.62x | 0.99x | 2.08x | 1.89x | 0.40x | 0.40x |
| Quick Ratio | 0.24x | 0.24x | 0.60x | 0.97x | 1.82x | 1.74x | 0.24x | 0.24x |
| Cash Conversion Cycle | 256.24 | 45.06 | -240.64 | -778.3 | 129.93 | 116.54 | 231.38 | -457.01 |
| Total Non-Current Liabilities | 30.03M | 9.24M | 10.49M | 865.02K | 8.65M | 10.55M | 75.22K | 0 |
| Long-Term Debt | 27.89M | 7.06M | 0 | 0 | 8.39M | 6.86M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 530.6K | 405.02K | 262.68K | 137.66K | 75.22K | 75.22K |
| Deferred Tax Liabilities | 2.08M | 1.43M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 57.4K | 749.55K | 9.96M | 460K | 0 | 3.55M | 0 | 57.59K |
| Total Liabilities | 68.57M | 50.35M | 52.38M | 31.85M | 15.72M | 21.32M | 18.1M | 2.77M |
| Total Debt | 47.19M | 13.74M | 7.81M | 405.02K | 9.88M | 8.28M | 7.39M | 0 |
| Net Debt | 44.4M | 11.6M | -9.33M | -23.44M | 456.53K | -5.06M | 3.68M | -6.07M |
| Debt / Equity | - | 1.71x | 0.45x | 0.01x | 0.59x | 0.66x | - | 0.00x |
| Debt / EBITDA | 113.79x | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | 107.05x | - | - | - | - | - | - | 0.51x |
| Interest Coverage | - | -1.39x | -5.66x | -48.96x | -33.41x | -25.40x | -31.52x | -79.35x |
| Total Equity | -1.68M▲ 0% | 8.02M▲ 577.0% | 17.47M▲ 117.8% | 35.54M▲ 103.5% | 16.7M▼ 53.0% | 12.48M▼ 25.3% | -7.47M▼ 159.8% | 3.37M▲ 0% |
| Equity Growth % | - | 576.97% | 117.84% | 103.47% | -53.01% | -25.28% | -159.84% | -393% |
| Book Value per Share | -16.81 | 32.60 | 32.71 | 32.64 | 8.07 | 5.74 | -0.93 | 0.08 |
| Total Shareholders' Equity | -1.68M | 8.02M | 17.47M | 35.54M | 16.7M | 12.48M | -7.47M | 3.37M |
| Common Stock | 0 | 29.12M | 971 | 2.07K | 208 | 298 | 1.05K | 4.23K |
| Retained Earnings | -1.68M | -41.12M | -61.7M | -70.69M | -90.73M | -98.89M | -113.21M | -110.96M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PTPI Cash Flow Statement
Petros Pharmaceuticals, Inc. (PTPI) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 8.02M | 2.53M | -15.31M | -11.86M | -12.8M | -7.63M | -2.6M | -2.6M |
| Operating CF Margin % | 57.08% | 16.26% | -160.11% | -151.86% | -213.57% | -130.99% | -50.92% | - |
| Operating CF Growth % | - | -68.43% | -704.36% | 22.5% | -7.88% | 40.41% | 65.87% | -31.49% |
| Net Income | -32.47M | -32.51M | -20.59M | -8.99M | -20.04M | -8.16M | -14.32M | -7.02M |
| Depreciation & Amortization | 8.06M | 5.29M | 6.66M | 6.88M | 5.72M | 3.42M | 2.94M | 667.29K |
| Stock-Based Compensation | 0 | 0 | 0 | 1.31M | 1.2M | 417.23K | 197.22K | 154.36K |
| Deferred Taxes | -6.94K | -645.87K | -1.43M | -9.48M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 42.55M | 17.3M | 5.65M | 186.82K | 3.63M | -3.92M | 4.05M | -1.97M |
| Working Capital Changes | 4.93M | 13.09M | -5.6M | -1.76M | -3.3M | 624.91K | 4.53M | 2.78M |
| Change in Receivables | 1.95M | 932.89K | -2.75M | 2.55M | 515.96K | -144.13K | 1.82M | 1.56M |
| Change in Inventory | 96.58K | 2.56M | 728.29K | 412.74K | -835.32K | 273.61K | 307.59K | 67.8K |
| Change in Payables | -965.04K | 2.02M | 2.22M | -1.05M | -2.75M | -93.15K | 615.68K | 933.66K |
| Cash from Investing | -1.88M | -71.54K | -4.63K | 0 | 0 | 0 | -24.59K | -5.45K |
| Capital Expenditures | -1.88M | -71.54K | -4.63K | 0 | 0 | 0 | -24.59K | -5.45K |
| CapEx % of Revenue | 13.35% | 0.46% | 0.05% | - | - | - | 0.48% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -2.55M | -3.11M | 30.3M | 18.57M | -1.62M | 11.54M | -7M | 7.02M |
| Debt Issued (Net) | -2.55M | -3.11M | 8.78M | -7.19M | -1.62M | -1.46M | -765.28K | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | -1000K | -1000K | -428.23K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -1.29B | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 21.52M | 4.01M | 0 | 15M | 1.29B | -117.31K |
| Net Change in Cash | 3.6M▲ 0% | -648.31K▼ 118.0% | 14.99M▲ 2412.8% | 6.71M▼ 55.3% | -14.42M▼ 315.0% | 3.91M▲ 127.1% | -9.63M▼ 346.2% | 2.18M▲ 0% |
| Free Cash Flow | 6.15M▲ 0% | 2.46M▼ 60.0% | -15.31M▼ 722.1% | -11.86M▲ 22.5% | -12.8M▼ 7.9% | -7.63M▲ 40.4% | -2.63M▲ 65.5% | -4.84M▲ 0% |
| FCF Margin % | 43.73% | 15.8% | -160.15% | -151.86% | -213.57% | -130.99% | -51.4% | -667.38% |
| FCF Growth % | - | -59.95% | -722.12% | 22.52% | -7.88% | 40.41% | 65.55% | 17.21% |
| FCF per Share | 61.45 | 10.00 | -28.67 | -10.89 | -6.18 | -3.50 | -0.33 | -0.33 |
| FCF Conversion (FCF/Net Income) | -0.25x | -0.08x | 0.74x | 1.32x | 0.64x | 0.93x | 0.18x | 0.69x |
| Interest Paid | 0 | 2.04M | 1.19M | 0 | 596.02K | 536.14K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PTPI Key Ratios
Petros Pharmaceuticals, Inc. (PTPI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1025.92% | -161.53% | -33.9% | -76.7% | -55.95% | -571.33% | -208.53% |
| Return on Invested Capital (ROIC) | -46.47% | -93.38% | -133.71% | -102.09% | -83.1% | -730.89% | -730.89% |
| Gross Margin | 18.35% | 57.67% | 79.52% | 61.79% | 71.98% | 76.28% | 63.5% |
| Net Margin | -208.71% | -215.35% | -115.05% | -334.4% | -140.2% | -280.1% | -968.2% |
| Debt / Equity | 1.71x | 0.45x | 0.01x | 0.59x | 0.66x | - | 0.00x |
| Interest Coverage | -1.39x | -5.66x | -48.96x | -33.41x | -25.40x | -31.52x | -79.35x |
| FCF Conversion | -0.08x | 0.74x | 1.32x | 0.64x | 0.93x | 0.18x | 0.69x |
| Revenue Growth | 10.86% | -38.63% | -18.29% | -23.29% | -2.83% | -12.2% | -81.97% |
PTPI Frequently Asked Questions
Petros Pharmaceuticals, Inc. (PTPI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Petros Pharmaceuticals, Inc. (PTPI) reported $0.7M in revenue for fiscal year 2024. This represents a 95% decrease from $14.1M in 2018.
Petros Pharmaceuticals, Inc. (PTPI) saw revenue decline by 12.2% over the past year.
Petros Pharmaceuticals, Inc. (PTPI) reported a net loss of $7.0M for fiscal year 2024.
Dividend & Returns
Yes, Petros Pharmaceuticals, Inc. (PTPI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Petros Pharmaceuticals, Inc. (PTPI) has a return on equity (ROE) of -571.3%. Negative ROE indicates the company is unprofitable.
Petros Pharmaceuticals, Inc. (PTPI) had negative free cash flow of $4.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More PTPI
Petros Pharmaceuticals, Inc. (PTPI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates